Program Manager at Ankasa Regenerative Therapeutics, Inc. - South San Francisco, California, United States
Stem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans, leading to clinical candidate ART352-L. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.